Jonathan Wolleben
Stock Analyst at Citizens
(4.65)
# 205
Out of 5,113 analysts
233
Total ratings
55.13%
Success rate
34.11%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $527 → $745 | $500.39 | +48.88% | 15 | Jan 20, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $108 → $105 | $52.97 | +98.24% | 18 | Jan 8, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $95 → $140 | $99.27 | +41.03% | 13 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $21 → $45 | $24.44 | +84.12% | 16 | Dec 17, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $141 → $167 | $105.53 | +58.25% | 6 | Dec 12, 2025 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $87 → $120 | $89.51 | +34.06% | 11 | Dec 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $6.09 | +474.71% | 9 | Nov 14, 2025 | |
| SVRA Savara | Maintains: Market Outperform | $11 → $10 | $5.85 | +70.94% | 10 | Nov 13, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $254 → $259 | $84.50 | +206.51% | 9 | Nov 11, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $14.94 | +87.42% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $69 → $102 | $83.12 | +22.72% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $6.18 | +126.54% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $6.76 | +269.82% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $9.61 | +108.12% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $10.85 | +167.28% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.67 | +390.46% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $27.18 | +91.32% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $8 | $3.31 | +141.69% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.68 | +377.61% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $1.07 | +1,301.87% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $5.66 | +235.69% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $36.07 | +5.35% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $44.56 | +12.21% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $66.22 | +35.91% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $132.22 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $511.70 | -5.22% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.64 | +1,149.80% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $30.26 | -20.69% | 1 | May 12, 2023 |
Madrigal Pharmaceuticals
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $500.39
Upside: +48.88%
Crinetics Pharmaceuticals
Jan 8, 2026
Maintains: Market Outperform
Price Target: $108 → $105
Current: $52.97
Upside: +98.24%
Mirum Pharmaceuticals
Dec 19, 2025
Maintains: Market Outperform
Price Target: $95 → $140
Current: $99.27
Upside: +41.03%
DBV Technologies
Dec 17, 2025
Maintains: Market Outperform
Price Target: $21 → $45
Current: $24.44
Upside: +84.12%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Market Outperform
Price Target: $141 → $167
Current: $105.53
Upside: +58.25%
Structure Therapeutics
Dec 12, 2025
Maintains: Market Outperform
Price Target: $87 → $120
Current: $89.51
Upside: +34.06%
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $6.09
Upside: +474.71%
Savara
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.85
Upside: +70.94%
Spruce Biosciences
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $84.50
Upside: +206.51%
KalVista Pharmaceuticals
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $14.94
Upside: +87.42%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $69 → $102
Current: $83.12
Upside: +22.72%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $6.18
Upside: +126.54%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $6.76
Upside: +269.82%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $9.61
Upside: +108.12%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $10.85
Upside: +167.28%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.67
Upside: +390.46%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $27.18
Upside: +91.32%
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $3.31
Upside: +141.69%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.68
Upside: +377.61%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.07
Upside: +1,301.87%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $5.66
Upside: +235.69%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $36.07
Upside: +5.35%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $44.56
Upside: +12.21%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $66.22
Upside: +35.91%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $132.22
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $511.70
Upside: -5.22%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.64
Upside: +1,149.80%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $30.26
Upside: -20.69%